← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence. (2022/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Ruxolitinib and tuberculosis: A case report with brief review. (2022/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fedratinib-induced orbital inflammation. (2022/06/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Trisomy 8-positive Polycythemia Vera Complicated with Intestinal Behçet's-like Disease: A New Perspective for a Clinical Approach. (2022/06/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transplantation algorithm for myelofibrosis in 2022 and beyond. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Contemporary and future strategies in polycythemia vera. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Considerations to comprehensive care for the older individual with myelofibrosis. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Addressing symptom burden in myeloproliferative neoplasms. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Challenges of diagnosing and managing pre-fibrotic myelofibrosis: A case-based and practical approach. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Accelerated and blast phase myeloproliferative neoplasms. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myeloproliferative neoplasms in adolescents and young adults. (2022/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel therapeutics and targets in myelofibrosis. (2022/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. State-of-the-Art Review on Myelofibrosis Therapies. (2022/05/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 10(9)/L): Final Analysis of an Open-Label Phase 2 Study. (2022/05/01) ♡
• Novel strategies for challenging scenarios encountered in managing myelofibrosis. (2022/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. (2022/04/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. (2022/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Extramedullary haematopoiesis within hepatic sinusoids of a patient with primary myelofibrosis. (2022/03/01) ♡
• Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. (2022/02/05) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Transplant indications, guidelines and recommendations: Caveat Emptor. (2022/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. (2022/02/01) ♡
• Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. (2022/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myeloproliferative Neoplasms with Monocytosis. (2022/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Immune reconstitution inflammatory syndrome (IRIS) in a patient with neuro pulmonary nocardiosis following hematopoietic cells transplantation (HCT). (2022/02/01) ♡
• Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. (2022/02/01) ♡
• Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia. (2022/02/01) ♡
• Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. (2022/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Megakaryocyte-bone cell interactions: lessons from mouse models of experimental myelofibrosis and related disorders. (2022/02/01) ♡
• Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. (2022/02/01) ♡
• Allogeneic Stem Cell Transplantation Combined With Transfusion of Mesenchymal Stem Cells in Primary Myelofibrosis: A Multicenter Retrospective Study. (2022/01/24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome. (2022/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data. (2022/01/01) ♡
• Aberrant expression of SPAG6 may affect the disease phenotype and serve as a tumor biomarker in BCR/ABL1-negative myeloproliferative neoplasms. (2022/01/01) ♡
• Conjugated polymers mediate intracellular Ca(2+) signals in circulating endothelial colony forming cells through the reactive oxygen species-dependent activation of Transient Receptor Potential Vanilloid 1 (TRPV1). (2022/01/01) ♡
• Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval. (2022/01/01) ♡
• The roles of sex and genetics in the MPN. (2022/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Lessons from mouse models of MPN. (2022/01/01) ♡
• Lab tests for MPN. (2022/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Transcriptional configurations of myeloproliferative neoplasms. (2022/01/01) ♡
• Targets in MPNs and potential therapeutics. (2022/01/01) ♡
• Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. (2022/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Durable remission following donor lymphocyte infusion for post-transplant relapse of acute myeloid leukemia developing from secondary myelofibrosis]. (2022/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. (2022-12-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. (2022-11-29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib (2022-11-17) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis (2022-11-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (2022-11-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Ropeginterferon Alfa 2b for Early Myelofibrosis (2022-10-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia (2022-10-05) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.